<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01926626</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00044174</org_study_id>
    <secondary_id>P50DA027840-01</secondary_id>
    <nct_id>NCT01926626</nct_id>
  </id_info>
  <brief_title>Evaluation of Moclobemide, a Reversible MAO-A Inhibitor, as an Adjunct to Nicotine Replacement Therapy in Female Smokers</brief_title>
  <acronym>RIMA</acronym>
  <official_title>Evaluation of Moclobemide, a Reversible MAO-A Inhibitor, as an Adjunct to Nicotine Replacement Therapy in Female Smokers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jed E. Rose</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Philip Morris USA, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed study will assess the efficacy of moclobemide, a selective, reversible MAO-A
      inhibitor, in facilitating smoking cessation in treatment-seeking female smokers. This
      rationale is based on several findings from previous work: 1) cigarette smoke contains
      constituents that inhibit both forms of the enzyme monoamine oxidase (MAO-A and MAO-B); 2)
      that severity of depression symptoms after smoking abstinence is correlated with the level of
      MAO-A inhibition previously obtained from smoking; 3) moclobemide, an MAO-A inhibitor was
      found efficacious in a smoking cessation treatment trial (Berlin et al., 1995); and 4) women
      show a greater association between smoking and depression than men and women smokers in our
      previous trials report smoking to alleviate symptoms of depression to a greater extent than
      men.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Continuous Four-week Abstinence From Smoking</measure>
    <time_frame>Weeks 6-10 post quit day</time_frame>
    <description>Number of participants who reported continuous four-week abstinence from smoking (weeks 6-10 post target quit date), confirmed by expired air carbon monoxide (CO).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Point Abstinence From Smoking at Six Months Post Quit</measure>
    <time_frame>7 day point abstinence from smoking at six months post quit</time_frame>
    <description>Number of participants who reported 7-day point abstinence from smoking at six months post quit, confirmed by expired air CO.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Continuous Ten Week Abstinence From Smoking</measure>
    <time_frame>10 weeks post quit day</time_frame>
    <description>Number of participants who reported continuous ten-week abstinence from smoking (weeks 1-10 post quit day), confirmed by expired air CO.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Change in Smoking Withdrawal Symptoms</measure>
    <time_frame>Quit day and 1 week, 3 weeks, 6 weeks, 10 weeks and 6 months post quit day</time_frame>
    <description>Withdrawal symptoms will be assessed by questionnaire on Quit Day, 1 week post quit, 3 weeks post quit, 6 weeks post quit,10 weeks post quit and 6 months post quit (if applicable) using the Shiffman-Jarvik questionnaire, which consists of 33-items rated from 1 to 7, where 1= not at all, 2= very little, 3= a little, 4= moderately, 5= a lot, 6= quite a lot, and 7= extremely. The 33 items are grouped into 8 subscales: Craving, Negative Affect, Appetite, Arousal, Somatic - Anxiety, Somatic - G.I., Somatic - Respiratory Tract, and Habit Withdrawal. The range of scores for each subscale will be 1-7, with higher scores indicating more of the withdrawal symptom having been experienced.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Change in Expired Air Carbon Monoxide (CO) During the First Week of Nicotine Patch Treatment.</measure>
    <time_frame>Baseline and 1 week</time_frame>
    <description>The initial response to nicotine patch will be assessed by looking at the percent change in expired air carbon monoxide (CO) at the end of week one (Study Visit 2) relative to baseline (Study Visit 1).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety of Moclobemide + Nicotine Patch</measure>
    <time_frame>1, 2, 4, 7 and 11 weeks after starting Moclobemide + Nicotine Patch</time_frame>
    <description>Safety of the moclobemide + nicotine patch treatment will be assessed by tabulating the number of participants rating side effects &gt; &quot;moderate&quot;.</description>
  </other_outcome>
  <other_outcome>
    <measure>Tolerability of Moclobemide + Nicotine Patch</measure>
    <time_frame>1, 2, 4, 7 and 11 weeks after starting Moclobemide + Nicotine Patch</time_frame>
    <description>Tolerability of the moclobemide + nicotine patch treatment will be assessed by tabulating the number of participants requiring dose reductions (or discontinuation of medication).</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Nicotine Dependence</condition>
  <arm_group>
    <arm_group_label>Nicotine Patch+Moclobemide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After 1 week of pre-cessation nicotine patch treatment (21 mg/24 h patches), participants will receive moclobemide (400 mg/day in 2 divided doses) for 11 weeks, ending 10 weeks after the target quit date. Nicotine patch treatment will continue at 21 mg/24 h for an additional week prior to the quit date, and then for 6 weeks after the quit date, followed by 14 mg/24 h for 2 weeks and 7 mg/24 h for 2 weeks. All treatment will terminate 10 weeks after the quit date.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine Patch</intervention_name>
    <description>Pre-Quit Period: 2 weeks of patch use (21mg/24hr)
Post Quit Period: 10 weeks of patch use (21mg/24hr for 6 weeks, 14mg/24hr for 2 weeks, and 7mg/24hr for 2 weeks)</description>
    <arm_group_label>Nicotine Patch+Moclobemide</arm_group_label>
    <other_name>Nicoderm</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moclobemide</intervention_name>
    <description>Pre-Quit Period: 1 week of moclobemide use (400 mg/day in 2 divided doses)
Post Quit Period: 10 weeks of moclobemide use (400 mg/day in 2 divided doses)</description>
    <arm_group_label>Nicotine Patch+Moclobemide</arm_group_label>
    <other_name>reversible MAO-A inhibitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have no known serious medical conditions;

          -  Female;

          -  Are 18-65 years old;

          -  Smoke an average of at least 20 cigarettes per day;

          -  Have smoked at least one cumulative year;

          -  Have a Fagerstrom Test for Nicotine Dependence score of at least 5;

          -  Have an expired air carbon monoxide (CO) reading of at least 10ppm;

          -  Able to read and understand English;

          -  Express a desire to quit smoking in the next thirty days.

        Potential subjects must agree to avoid the following during their participation in this
        study:

          -  excessive alcohol consumption;

          -  use of other antidepressants;

          -  general anesthesia;

          -  participation in any other nicotine-related modification strategy outside of this
             protocol;

          -  use of tobacco products other than cigarettes, including pipe tobacco, cigars,
             e-cigarettes, snuff, and chewing tobacco;

          -  use of experimental (investigational) drugs or devices;

          -  use of illegal drugs;

          -  cimetidine;

          -  Tyramine rich foods;

          -  use of opiate medications.

        Exclusion Criteria:

          -  Hypertension;

          -  Hypotension with symptoms;

          -  Coronary heart disease;

          -  Lifetime history of heart attack;

          -  Cardiac rhythm disorder;

          -  Chest pains;

          -  Cardiac (heart) disorder;

          -  Active skin disorder;

          -  Liver or kidney disorder;

          -  Gastrointestinal problems or disease other than gastroesophageal reflux or heartburn;

          -  Active ulcers in the past 30 days;

          -  Currently Symptomatic lung disorder/disease;

          -  Brain abnormality;

          -  Migraine headaches that occur more frequently than once per week;

          -  Recent, unexplained fainting spells;

          -  Problems giving blood samples;

          -  Diabetes (unless controlled by diet and exercise alone);

          -  Current cancer or treatment for cancer in the past six;

          -  Other major medical condition;

          -  Current psychiatric disease;

          -  Suicidal ideation (within the past 10 years) or lifetime occurrence of attempted
             suicide;

          -  Current depression;

          -  Bulimia or anorexia;

          -  Use (within the past 45 days) of psychiatric medications including antidepressants and
             anti-psychotics;

          -  Use (within the past 30 days) of:

               -  Illegal drugs (or if the urine drug screen is positive for tetrahydrocannabinol
                  (THC), Cocaine, Amphetamine, Opiates, Methamphetamines, phencyclidine (PCP),
                  Benzodiazepines, or Barbiturates),

               -  Experimental (investigational) drugs;

               -  Any medications that are known to affect smoking cessation (e.g. clonidine);

               -  Smokeless tobacco (chewing tobacco, snuff), pipes or e-cigarettes;

               -  Wellbutrin, bupropion, Zyban, Chantix, nicotine replacement therapy or any other
                  smoking cessation aid.

          -  Use of opiate medications for pain or sleep (non-opiate medication for pain or sleep
             will be allowed) within the past 14 days;

          -  Smokes more than one cigar a month.

          -  Alcohol abuse;

          -  Significant adverse reaction to nicotine patches, in the past.

          -  Known hypersensitivity to moclobemide or other MAO-A inhibitors.

          -  Current participation or recent participation (in the past 30 days) in another smoking
             study at our center or another research facility.

          -  Current participation or recent participation (in the past six months) in another
             medical research study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jed E Rose, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke Center for Smoking Cessation</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Center forSmoking Cessation</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Center for Smoking Cessation</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 19, 2013</study_first_submitted>
  <study_first_submitted_qc>August 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 21, 2013</study_first_posted>
  <results_first_submitted>June 8, 2015</results_first_submitted>
  <results_first_submitted_qc>July 1, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 29, 2015</results_first_posted>
  <last_update_submitted>August 17, 2017</last_update_submitted>
  <last_update_submitted_qc>August 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Duke University</investigator_affiliation>
    <investigator_full_name>Jed E. Rose</investigator_full_name>
    <investigator_title>Professor, Department of Psychiatry and Behavioral Sciences</investigator_title>
  </responsible_party>
  <keyword>Nicotine addiction</keyword>
  <keyword>Smoking Cessation</keyword>
  <keyword>Quit Smoking</keyword>
  <keyword>moclobemide</keyword>
  <keyword>Nicotine Patch</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
    <mesh_term>Moclobemide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Of the 76 participants who were enrolled, 38 participants attended Study Session 1: 1 participant voluntarily withdrew prior to Study Session 1, 3 participants were lost to contact prior to Study Session 1, and 34 were withdrawn from the study by the PI or medical staff because they did not meet inclusion criteria or met exclusion criteria.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Nicotine Patch+Moclobemide</title>
          <description>After 1 week of pre-cessation nicotine patch treatment (21 mg/24 h patches), participants will receive moclobemide (400 mg/day in 2 divided doses) for 11 weeks, ending 10 weeks after the target quit date. Nicotine patch treatment will continue at 21 mg/24 h for an additional week prior to the quit date, and then for 6 weeks after the quit date, followed by 14 mg/24 h for 2 weeks and 7 mg/24 h for 2 weeks. All treatment will terminate 10 weeks after the quit date.
Nicotine Patch: Pre-Quit Period: 2 weeks of patch use (21mg/24hr)
Post Quit Period: 10 weeks of patch use (21mg/24hr for 6 weeks, 14mg/24hr for 2 weeks, and 7mg/24hr for 2 weeks)
Moclobemide: Pre-Quit Period: 1 week of moclobemide use (400 mg/day in 2 divided doses)
Post Quit Period: 10 weeks of moclobemide use (400 mg/day in 2 divided doses)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Moclobemide</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Nicotine Patch+Moclobemide</title>
          <description>After 1 week of pre-cessation nicotine patch treatment (21 mg/24 h patches), participants will receive moclobemide (400 mg/day in 2 divided doses) for 11 weeks, ending 10 weeks after the target quit date. Nicotine patch treatment will continue at 21 mg/24 h for an additional week prior to the quit date, and then for 6 weeks after the quit date, followed by 14 mg/24 h for 2 weeks and 7 mg/24 h for 2 weeks. All treatment will terminate 10 weeks after the quit date.
Nicotine Patch: Pre-Quit Period: 2 weeks of patch use (21mg/24hr)
Post Quit Period: 10 weeks of patch use (21mg/24hr for 6 weeks, 14mg/24hr for 2 weeks, and 7mg/24hr for 2 weeks)
Moclobemide: Pre-Quit Period: 1 week of moclobemide use (400 mg/day in 2 divided doses)
Post Quit Period: 10 weeks of moclobemide use (400 mg/day in 2 divided doses)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="38"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.53" spread="9.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Continuous Four-week Abstinence From Smoking</title>
        <description>Number of participants who reported continuous four-week abstinence from smoking (weeks 6-10 post target quit date), confirmed by expired air carbon monoxide (CO).</description>
        <time_frame>Weeks 6-10 post quit day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nicotine Patch+Moclobemide</title>
            <description>After 1 week of pre-cessation nicotine patch treatment (21 mg/24 h patches), participants will receive moclobemide (400 mg/day in 2 divided doses) for 11 weeks, ending 10 weeks after the target quit date. Nicotine patch treatment will continue at 21 mg/24 h for an additional week prior to the quit date, and then for 6 weeks after the quit date, followed by 14 mg/24 h for 2 weeks and 7 mg/24 h for 2 weeks. All treatment will terminate 10 weeks after the quit date.
Nicotine Patch: Pre-Quit Period: 2 weeks of patch use (21mg/24hr)
Post Quit Period: 10 weeks of patch use (21mg/24hr for 6 weeks, 14mg/24hr for 2 weeks, and 7mg/24hr for 2 weeks)
Moclobemide: Pre-Quit Period: 1 week of moclobemide use (400 mg/day in 2 divided doses)
Post Quit Period: 10 weeks of moclobemide use (400 mg/day in 2 divided doses)</description>
          </group>
        </group_list>
        <measure>
          <title>Continuous Four-week Abstinence From Smoking</title>
          <description>Number of participants who reported continuous four-week abstinence from smoking (weeks 6-10 post target quit date), confirmed by expired air carbon monoxide (CO).</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Point Abstinence From Smoking at Six Months Post Quit</title>
        <description>Number of participants who reported 7-day point abstinence from smoking at six months post quit, confirmed by expired air CO.</description>
        <time_frame>7 day point abstinence from smoking at six months post quit</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nicotine Patch+Moclobemide</title>
            <description>After 1 week of pre-cessation nicotine patch treatment (21 mg/24 h patches), participants will receive moclobemide (400 mg/day in 2 divided doses) for 11 weeks, ending 10 weeks after the target quit date. Nicotine patch treatment will continue at 21 mg/24 h for an additional week prior to the quit date, and then for 6 weeks after the quit date, followed by 14 mg/24 h for 2 weeks and 7 mg/24 h for 2 weeks. All treatment will terminate 10 weeks after the quit date.
Nicotine Patch: Pre-Quit Period: 2 weeks of patch use (21mg/24hr)
Post Quit Period: 10 weeks of patch use (21mg/24hr for 6 weeks, 14mg/24hr for 2 weeks, and 7mg/24hr for 2 weeks)
Moclobemide: Pre-Quit Period: 1 week of moclobemide use (400 mg/day in 2 divided doses)
Post Quit Period: 10 weeks of moclobemide use (400 mg/day in 2 divided doses)</description>
          </group>
        </group_list>
        <measure>
          <title>Point Abstinence From Smoking at Six Months Post Quit</title>
          <description>Number of participants who reported 7-day point abstinence from smoking at six months post quit, confirmed by expired air CO.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Continuous Ten Week Abstinence From Smoking</title>
        <description>Number of participants who reported continuous ten-week abstinence from smoking (weeks 1-10 post quit day), confirmed by expired air CO.</description>
        <time_frame>10 weeks post quit day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nicotine Patch+Moclobemide</title>
            <description>After 1 week of pre-cessation nicotine patch treatment (21 mg/24 h patches), participants will receive moclobemide (400 mg/day in 2 divided doses) for 11 weeks, ending 10 weeks after the target quit date. Nicotine patch treatment will continue at 21 mg/24 h for an additional week prior to the quit date, and then for 6 weeks after the quit date, followed by 14 mg/24 h for 2 weeks and 7 mg/24 h for 2 weeks. All treatment will terminate 10 weeks after the quit date.
Nicotine Patch: Pre-Quit Period: 2 weeks of patch use (21mg/24hr)
Post Quit Period: 10 weeks of patch use (21mg/24hr for 6 weeks, 14mg/24hr for 2 weeks, and 7mg/24hr for 2 weeks)
Moclobemide: Pre-Quit Period: 1 week of moclobemide use (400 mg/day in 2 divided doses)
Post Quit Period: 10 weeks of moclobemide use (400 mg/day in 2 divided doses)</description>
          </group>
        </group_list>
        <measure>
          <title>Continuous Ten Week Abstinence From Smoking</title>
          <description>Number of participants who reported continuous ten-week abstinence from smoking (weeks 1-10 post quit day), confirmed by expired air CO.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Change in Smoking Withdrawal Symptoms</title>
        <description>Withdrawal symptoms will be assessed by questionnaire on Quit Day, 1 week post quit, 3 weeks post quit, 6 weeks post quit,10 weeks post quit and 6 months post quit (if applicable) using the Shiffman-Jarvik questionnaire, which consists of 33-items rated from 1 to 7, where 1= not at all, 2= very little, 3= a little, 4= moderately, 5= a lot, 6= quite a lot, and 7= extremely. The 33 items are grouped into 8 subscales: Craving, Negative Affect, Appetite, Arousal, Somatic - Anxiety, Somatic - G.I., Somatic - Respiratory Tract, and Habit Withdrawal. The range of scores for each subscale will be 1-7, with higher scores indicating more of the withdrawal symptom having been experienced.</description>
        <time_frame>Quit day and 1 week, 3 weeks, 6 weeks, 10 weeks and 6 months post quit day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nicotine Patch+Moclobemide</title>
            <description>After 1 week of pre-cessation nicotine patch treatment (21 mg/24 h patches), participants will receive moclobemide (400 mg/day in 2 divided doses) for 11 weeks, ending 10 weeks after the target quit date. Nicotine patch treatment will continue at 21 mg/24 h for an additional week prior to the quit date, and then for 6 weeks after the quit date, followed by 14 mg/24 h for 2 weeks and 7 mg/24 h for 2 weeks. All treatment will terminate 10 weeks after the quit date.
Nicotine Patch: Pre-Quit Period: 2 weeks of patch use (21mg/24hr)
Post Quit Period: 10 weeks of patch use (21mg/24hr for 6 weeks, 14mg/24hr for 2 weeks, and 7mg/24hr for 2 weeks)
Moclobemide: Pre-Quit Period: 1 week of moclobemide use (400 mg/day in 2 divided doses)
Post Quit Period: 10 weeks of moclobemide use (400 mg/day in 2 divided doses)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Change in Smoking Withdrawal Symptoms</title>
          <description>Withdrawal symptoms will be assessed by questionnaire on Quit Day, 1 week post quit, 3 weeks post quit, 6 weeks post quit,10 weeks post quit and 6 months post quit (if applicable) using the Shiffman-Jarvik questionnaire, which consists of 33-items rated from 1 to 7, where 1= not at all, 2= very little, 3= a little, 4= moderately, 5= a lot, 6= quite a lot, and 7= extremely. The 33 items are grouped into 8 subscales: Craving, Negative Affect, Appetite, Arousal, Somatic - Anxiety, Somatic - G.I., Somatic - Respiratory Tract, and Habit Withdrawal. The range of scores for each subscale will be 1-7, with higher scores indicating more of the withdrawal symptom having been experienced.</description>
          <units>percentage of change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Craving -- % change 1 week from Quit Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.07" spread="7.928"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Craving -- % change 3 weeks from Quit Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.18" spread="4.144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Craving -- % change 6 weeks from Quit Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.24" spread="4.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Craving -- % change 10 weeks from Quit Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.41" spread="6.912"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Craving -- % change 6 months from Quit Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.71" spread="63.690"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative Affect -- % change 1 week from Quit Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.82" spread="4.057"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative Affect -- % change 3 weeks from Quit Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.26" spread="4.327"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative Affect -- % change 6 weeks from Quit Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.53" spread="4.051"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative Affect -- % change 10 weeks from Quit Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.92" spread="4.968"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative Affect -- % change 6 months from Quit Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.87" spread="65.334"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Appetite -- % change 1 week from Quit Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.40" spread="5.486"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Appetite -- % change 3 weeks from Quit Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.39" spread="7.881"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Appetite -- % change 6 weeks from Quit Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.07" spread="8.819"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Appetite -- % change 10 weeks from Quit Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.73" spread="16.033"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Appetite -- % change 6 months from Quit Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.24" spread="74.446"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arousal -- % change 1 week from Quit Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.81" spread="8.824"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arousal -- % change 3 weeks from Quit Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.03" spread="7.004"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arousal -- % change 6 weeks from Quit Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.99" spread="6.915"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arousal -- % change 10 weeks from Quit Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.95" spread="6.715"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arousal -- % change 6 months from Quit Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="190.88" spread="78.496"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxiety -- % change 1 week from Quit Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.65" spread="3.803"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxiety -- % change 3 weeks from Quit Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.80" spread="4.788"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxiety -- % change 6 weeks from Quit Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.48" spread="5.098"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxiety -- % change 10 weeks from Quit Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.44" spread="6.375"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxiety -- % change 6 months from Quit Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-38.79" spread="19.553"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal -- % change 1 week from Quit Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.80" spread="3.365"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal -- % change 3 weeks from Quit Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.03" spread="6.602"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal -- % change 6 weeks from Quit Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.55" spread="16.189"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal - % change 10 weeks from Quit Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.20" spread="5.100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal - % change 6 months from Quit Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.66" spread="18.204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory -- % change 1 week from Quit Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.26" spread="6.978"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory -- % change 3 weeks from Quit Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.06" spread="11.161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory -- % change 6 weeks from Quit Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.16" spread="8.628"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory -- % change 10 weeks from Quit Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.28" spread="8.696"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory -- % change 6 months from Quit Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-38.79" spread="19.553"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Habit -- % change 1 week from Quit Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.26" spread="7.272"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Habit -- % change 3 weeks from Quit Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.41" spread="6.309"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Habit -- % change 6 weeks from Quit Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.22" spread="7.705"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Habit -- % change 10 weeks from Quit Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.49" spread="14.642"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Habit -- % change 6 months from Quit Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-38.79" spread="19.553"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Safety of Moclobemide + Nicotine Patch</title>
        <description>Safety of the moclobemide + nicotine patch treatment will be assessed by tabulating the number of participants rating side effects &gt; &quot;moderate&quot;.</description>
        <time_frame>1, 2, 4, 7 and 11 weeks after starting Moclobemide + Nicotine Patch</time_frame>
        <population>Participants who received Moclobemide.</population>
        <group_list>
          <group group_id="O1">
            <title>Nicotine Patch+Moclobemide</title>
            <description>After 1 week of pre-cessation nicotine patch treatment (21 mg/24 h patches), participants will receive moclobemide (400 mg/day in 2 divided doses) for 11 weeks, ending 10 weeks after the target quit date. Nicotine patch treatment will continue at 21 mg/24 h for an additional week prior to the quit date, and then for 6 weeks after the quit date, followed by 14 mg/24 h for 2 weeks and 7 mg/24 h for 2 weeks. All treatment will terminate 10 weeks after the quit date.
Nicotine Patch: Pre-Quit Period: 2 weeks of patch use (21mg/24hr)
Post Quit Period: 10 weeks of patch use (21mg/24hr for 6 weeks, 14mg/24hr for 2 weeks, and 7mg/24hr for 2 weeks)
Moclobemide: Pre-Quit Period: 1 week of moclobemide use (400 mg/day in 2 divided doses)
Post Quit Period: 10 weeks of moclobemide use (400 mg/day in 2 divided doses)</description>
          </group>
        </group_list>
        <measure>
          <title>Safety of Moclobemide + Nicotine Patch</title>
          <description>Safety of the moclobemide + nicotine patch treatment will be assessed by tabulating the number of participants rating side effects &gt; &quot;moderate&quot;.</description>
          <population>Participants who received Moclobemide.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Change in Expired Air Carbon Monoxide (CO) During the First Week of Nicotine Patch Treatment.</title>
        <description>The initial response to nicotine patch will be assessed by looking at the percent change in expired air carbon monoxide (CO) at the end of week one (Study Visit 2) relative to baseline (Study Visit 1).</description>
        <time_frame>Baseline and 1 week</time_frame>
        <population>Participants who received Moclobemide.</population>
        <group_list>
          <group group_id="O1">
            <title>Nicotine Patch+Moclobemide</title>
            <description>After 1 week of pre-cessation nicotine patch treatment (21 mg/24 h patches), participants will receive moclobemide (400 mg/day in 2 divided doses) for 11 weeks, ending 10 weeks after the target quit date. Nicotine patch treatment will continue at 21 mg/24 h for an additional week prior to the quit date, and then for 6 weeks after the quit date, followed by 14 mg/24 h for 2 weeks and 7 mg/24 h for 2 weeks. All treatment will terminate 10 weeks after the quit date.
Nicotine Patch: Pre-Quit Period: 2 weeks of patch use (21mg/24hr)
Post Quit Period: 10 weeks of patch use (21mg/24hr for 6 weeks, 14mg/24hr for 2 weeks, and 7mg/24hr for 2 weeks)
Moclobemide: Pre-Quit Period: 1 week of moclobemide use (400 mg/day in 2 divided doses)
Post Quit Period: 10 weeks of moclobemide use (400 mg/day in 2 divided doses)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Change in Expired Air Carbon Monoxide (CO) During the First Week of Nicotine Patch Treatment.</title>
          <description>The initial response to nicotine patch will be assessed by looking at the percent change in expired air carbon monoxide (CO) at the end of week one (Study Visit 2) relative to baseline (Study Visit 1).</description>
          <population>Participants who received Moclobemide.</population>
          <units>percentage of change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.38" spread="5.551"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Tolerability of Moclobemide + Nicotine Patch</title>
        <description>Tolerability of the moclobemide + nicotine patch treatment will be assessed by tabulating the number of participants requiring dose reductions (or discontinuation of medication).</description>
        <time_frame>1, 2, 4, 7 and 11 weeks after starting Moclobemide + Nicotine Patch</time_frame>
        <population>Participants who received Moclobemide.</population>
        <group_list>
          <group group_id="O1">
            <title>Nicotine Patch+Moclobemide</title>
            <description>After 1 week of pre-cessation nicotine patch treatment (21 mg/24 h patches), participants will receive moclobemide (400 mg/day in 2 divided doses) for 11 weeks, ending 10 weeks after the target quit date. Nicotine patch treatment will continue at 21 mg/24 h for an additional week prior to the quit date, and then for 6 weeks after the quit date, followed by 14 mg/24 h for 2 weeks and 7 mg/24 h for 2 weeks. All treatment will terminate 10 weeks after the quit date.
Nicotine Patch: Pre-Quit Period: 2 weeks of patch use (21mg/24hr)
Post Quit Period: 10 weeks of patch use (21mg/24hr for 6 weeks, 14mg/24hr for 2 weeks, and 7mg/24hr for 2 weeks)
Moclobemide: Pre-Quit Period: 1 week of moclobemide use (400 mg/day in 2 divided doses)
Post Quit Period: 10 weeks of moclobemide use (400 mg/day in 2 divided doses)</description>
          </group>
        </group_list>
        <measure>
          <title>Tolerability of Moclobemide + Nicotine Patch</title>
          <description>Tolerability of the moclobemide + nicotine patch treatment will be assessed by tabulating the number of participants requiring dose reductions (or discontinuation of medication).</description>
          <population>Participants who received Moclobemide.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Subjects were receiving study drugs for twelve weeks. At each study session during this period subjects completed a questionnaire about side effects. Subjects were also told to contact us between study sessions if side effects were bothersome.</time_frame>
      <desc>One subject discontinued study participation after the first study session; therefore, no side effects data pertaining to study interventions were collected for this subject.</desc>
      <group_list>
        <group group_id="E1">
          <title>Nicotine Patch+Moclobemide</title>
          <description>After 1 week of pre-cessation nicotine patch treatment (21 mg/24 h patches), participants will receive moclobemide (400 mg/day in 2 divided doses) for 11 weeks, ending 10 weeks after the target quit date. Nicotine patch treatment will continue at 21 mg/24 h for an additional week prior to the quit date, and then for 6 weeks after the quit date, followed by 14 mg/24 h for 2 weeks and 7 mg/24 h for 2 weeks. All treatment will terminate 10 weeks after the quit date.
Nicotine Patch: Pre-Quit Period: 2 weeks of patch use (21mg/24hr)
Post Quit Period: 10 weeks of patch use (21mg/24hr for 6 weeks, 14mg/24hr for 2 weeks, and 7mg/24hr for 2 weeks)
Moclobemide: Pre-Quit Period: 1 week of moclobemide use (400 mg/day in 2 divided doses)
Post Quit Period: 10 weeks of moclobemide use (400 mg/day in 2 divided doses)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Heartburn</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Increased appetite</sub_title>
                <counts group_id="E1" events="11" subjects_affected="7" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Loss of appetite</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="18" subjects_affected="9" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" events="19" subjects_affected="10" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle / joint pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="21" subjects_affected="12" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Tiredness</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Nightmares</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Vivid dreams</sub_title>
                <counts group_id="E1" events="27" subjects_affected="13" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="11" subjects_affected="7" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Excessive sweating</sub_title>
                <counts group_id="E1" events="14" subjects_affected="4" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Altered taste</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Agitation / restlessness</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Itching at patch site</sub_title>
                <counts group_id="E1" events="14" subjects_affected="11" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Rash at patch site</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jed E. Rose</name_or_title>
      <organization>Duke Center for Smoking Cessation</organization>
      <phone>919-668-5055</phone>
      <email>jed.rose@duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

